Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

New England Journal of Medicine

Volumn 358, Issue 24, 2008, Pages 2560-2572

  Patel, Anushka ^a   MacMahon, Stephen ^a   Chalmers, John ^a   Neal, Bruce ^a   Billot, Laurent ^a   Woodward, Mark ^a,b   Marre, Michel ^c   Cooper, Mark ^d   Glasziou, Paul ^e,f   Grobbee, Diederick ^g   Hamet, Pavel ^h   Harrap, Stephen ⁱ   Heller, Simon ^j   Liu, Lisheng ^k   Mancia, Giuseppe ^l   Mogensen, Carl Erik ^m   Pan, Changyu ⁿ   Poulter, Neil ^o   Rodgers, Anthony ^p   Williams, Bryan ^q   Bompoint, Severine ^r   De Galan, Bastiaan E ^r,s   Joshi, Rohina ^a   Travert, Florence ^c   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BICHAT HOSPITAL   (France)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k Chinese Hypertension League Institute   (China)

^l SAN GERARDO HOSPITAL   (Italy)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ CHINESE PLA GENERAL HOSPITAL   (China)

^o ST MARY S HOSPITAL   (United Kingdom)

^p UNIVERSITY OF AUCKLAND   (New Zealand)

^q UNIVERSITY OF LEICESTER   (United Kingdom)

^r GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

^s RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; PERINDOPRIL; PRETERAX;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INCIDENCE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STANDARD; STATISTICAL SIGNIFICANCE; STROKE; VASCULAR DISEASE;

EID: 45149133036     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0802987     Document Type: Article

References (34)

1. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-62.
2. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544-50.
3. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994;154:2473-9.
4. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
5. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients. Diabetes Care 2000;23:Suppl 2:B21-B29.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. [Erratum, Lancet 1999;354:602.]
7. Idem. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65. [Erratum, Lancet 1998;352:1558.]
8. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med 1997;157:181-8.
9. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
10. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38.
11. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:Suppl:789-830.
12. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30:Suppl 1:S4-S41.
13. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
14. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.
15. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.
16. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia 2001;44:1118-20.
17. Wales External Quality Assurance Scheme home page. (Accessed May 19, 2008, at http://www.weqas.com.)
18. Woodward M. Epidemiology: study design and data analysis. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC Press, 2005.
19. Schulz KF, Grimes DA. Multiplicity in randomised trials. I. Endpoints and treatments. Lancet 2005;365:1591-5.
20. National Institutes of Health. For Safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. 2008. (Accessed May 19, 2008, at http://www.nih.gov/news/health/ feb2008/nhlbi-06.htm.)
21. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
22. Home P. Safety of very tight blood glucose control in type 2 diabetes. BMJ 2008;336:458-9.
23. Gerstein H, Mann J, Yi Q, et al. Albuminuria and risk of CV events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421-6.
24. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-9. [Erratum, Lancet 2000;356:860.]
26. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
27. Stolk RP, Vingerling JR, Cruickshank JK, et al. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials 2007;28:6-17.
28. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314-22.
29. Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med 2002;19:752-7.
30. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004;58:833-7.
31. Wascher TC, Boes U. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. Clin Physiol Funct Imaging 2005;25:40-6.
32. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
33. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prespectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9.
34. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. [Erratum, Lancet 2005;366:1358.]